R. Yelensky

Elisabeth Brambilla, Stéphane Vignot, Roman Yelensky, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

recurrent alterations in antiapoptotic and chromatin-remodeling genes Targeted genomic sequencing of pediatric Burkitt lymphoma identifies

M. Rubin, R. Yelensky, E. Cesarman, 2013 .

Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes.

M. Rubin, P. Stephens, R. Yelensky, 2012, Blood.

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal

Philip J. Stephens, Doron Lipson, Jean-Charles Soria, 2018, PLoS Comput. Biol..

Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias

S. Armstrong, P. Stephens, R. Yelensky, 2016, Leukemia.

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

Howard Kaufman, Shridar Ganesan, Joseph R. Bertino, 2016, The oncologist.

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

R. Yelensky, J. Lee, V. Miller, 2016, Molecular Cancer Therapeutics.

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.

R. Yelensky, J. Lee, V. Miller, 2016, Cancer research.

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma

James X. Sun, P. Stephens, R. Yelensky, 2016, Oncology.

Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes.

James X. Sun, R. Yelensky, D. Lipson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

P. Stephens, R. Yelensky, D. Lipson, 2016, Cancer.

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Sanjay Goel, Kai Wang, Amit Verma, 2015, Cancer discovery.

Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification

P. Stephens, R. Yelensky, Bahar Yilmazel, 2015, Oncoscience.

Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine

R. Yelensky, J. O’Shaughnessy, J. Pippen, 2015, Cancer medicine.

Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies

P. Stephens, R. Yelensky, D. Lipson, 2014, Journal of Clinical Pathology.

Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer

P. Stephens, R. Yelensky, D. Lipson, 2014, Journal of Clinical Pathology.

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

P. Stephens, R. Yelensky, L. Pusztai, 2014, The oncologist.

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

P. Stephens, R. Yelensky, V. Valero, 2016, Oncoscience.

Abstract 1893: A computational method for somatic versus germline variant status determination from targeted next-generation sequencing of clinical cancer specimens without a matched normal control

James X. Sun, P. Stephens, R. Yelensky, 2014 .

Companion Diagnostics and Cancer Biomarkers Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

G. Mills, P. Stephens, R. Yelensky, 2014 .

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

P. Stephens, R. Yelensky, R. Kurzrock, 2014, Oncotarget.

Abstract A23: Comprehensive next-generation sequencing-based genomic profiling identifies actionable genomic alterations in diverse pediatric tumor types: The Foundation Medicine (FMI) experience

P. Stephens, R. Yelensky, V. Miller, 2014 .

Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Funda Meric-Bernstam, Gordon B Mills, Xiaoping Su, 2014, Molecular Cancer Therapeutics.

Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents

P. Stephens, R. Yelensky, J. Lee, 2014, Molecular Cancer Therapeutics.

Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.

R. Yelensky, S. Ou, D. Lipson, 2014 .

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

P. Stephens, R. Yelensky, D. Lipson, 2016, The oncologist.

Unique genomic features in adolescent and young adult, as compared to older adult, non‐Hodgkin lymphoma and potential therapeutic targets

P. Stephens, R. Yelensky, D. Lipson, 2017, British journal of haematology.

Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Cancer Positive Breast − in Pretreated Advanced Estrogen Receptor Mutations α Emergence of Constitutively Active Estrogen Receptor-Updated

Funda Meric-Bernstam, Rinath Jeselsohn, Lajos Pusztai, 2014 .

Segal and Dowsett , p . 1724 Emergence of Constitutively Active Estrogen Receptor-a Mutations in Pretreated Advanced Estrogen Receptor – Positive Breast Cancer

James X. Sun, P. Stephens, R. Yelensky, 2014 .

Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP).

James X. Sun, R. Yelensky, V. Miller, 2016 .

The role of the CD58 locus in multiple sclerosis

Margaret A. Pericak-Vance, Stephen L. Hauser, Jorge R. Oksenberg, 2009, Proceedings of the National Academy of Sciences.

Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform

A. Zelenetz, P. Stephens, R. Yelensky, 2013 .

Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2013 .

Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.

R. Yelensky, R. Karchin, C. Tokheim, 2015 .

Clinical next‐generation sequencing successfully applied to fine‐needle aspirations of pulmonary and pancreatic neoplasms

P. Stephens, R. Yelensky, D. Lipson, 2013, Cancer cytopathology.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

S. Mallal, R. Yelensky, S. Loi, 2019, Clinical Cancer Research.

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms

R. Yelensky, V. Valero, V. Miller, 2014, Oncotarget.

Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

for Acquired Endocrine Resistance in Breast Cancer : A Novel Mechanism α D 538 G Mutation in Estrogen Receptor-Updated

R. Yelensky, V. Miller, R. Jeselsohn, 2013 .

Priority Report D 538 GMutation in EstrogenReceptor-a : ANovelMechanism for Acquired Endocrine Resistance in Breast Cancer

R. Yelensky, V. Miller, R. Jeselsohn, 2013 .

Germline variants in cancer risk genes detected by NGS-based comprehensive tumor genomic profiling (CGP).

James X. Sun, R. Yelensky, J. Boyd, 2015 .

Comprehensive genomic profiling of 443 cases of renal cell carcinoma to reveal frequent clinically relevant genomic alterations.

R. Yelensky, T. Choueiri, D. Lipson, 2015 .

Next-generation sequencing to identify molecular alterations in DNA repair and chromatin maintenance genes associated with pathologic complete response (pT0) to neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in muscle-invasive bladder cancer (MIBC).

Roland L. Dunbrack, R. Yelensky, E. Plimack, 2014 .

Comprehensive next-generation sequencing for clinically actionable mutations from formalin-fixed cancer tissues.

R. Yelensky, M. Cronin, M. Jarosz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

GeneXPress : A Visualization and Statistical Analysis Tool for Gene Expression and Sequence Data

D. Koller, N. Friedman, A. Regev, 2022 .

Comprehensive genomic profiling of solid tumors from 677 adolescents and young adults for revealing a distinct spectrum of targetable genomic alterations.

R. Yelensky, D. Lipson, V. Miller, 2014 .

Patient Derived Xenograft (PDX) Models Faithfully Recapitulate The Genetic Composition Of Primary AML

S. Armstrong, P. Stephens, R. Yelensky, 2013 .

Abstract PD02-07: Next-generation sequencing of FFPE breast cancers demonstrates high concordance with FISH in callingHER2amplifications and commonly detects other clinically relevant genomic alterations

R. Yelensky, M. Cronin, M. Jarosz, 2012 .

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

James X. Sun, Chang S. Chan, A. Vazquez, 2016, The oncologist.

Abstract S3-6: Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease

R. Yelensky, M. Cronin, H. Gómez, 2012 .

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder to reveal frequency of clinically relevant genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples.

R. Yelensky, D. Lipson, V. Miller, 2013 .

Comprehensive genomic profiling of anal squamous cell carcinoma to reveal frequency of clinically relevant genomic alterations in the PI3K/mTOR pathway.

James X. Sun, P. Stephens, R. Yelensky, 2015 .

Abstract 4699: Analytical validation of solid tumor fusion gene detection in a comprehensive NGS-based clinical cancer genomic test

M. Ladanyi, P. Stephens, R. Yelensky, 2014 .

Concordance of driver mutations in primary and matched metastasis from patients with non-small cell lung cancer (NSCLC) using next-generation sequencing (NGS).

P. Stephens, R. Yelensky, M. Cronin, 2012 .

Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy.

R. Yelensky, V. Miller, F. Meric-Bernstam, 2015 .

Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.

Roland L. Dunbrack, R. Yelensky, Yan Zhou, 2015 .

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.

R. Yelensky, V. Miller, R. Kurzrock, 2016, Cancer research.

Unique genomic features in adolescent and young adult, as compared to older adult, non‐Hodgkin lymphoma and potential therapeutic targets

P. Stephens, R. Yelensky, D. Lipson, 2017, British journal of haematology.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

L. Garraway, X. Mu, R. Yelensky, 2017, Science Translational Medicine.

squamous cell carcinoma identifies novel genetic alterations

P. Stephens, R. Yelensky, C. Boshoff, 2022 .

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.

R. Yelensky, V. Miller, R. Jeselsohn, 2013, Cancer research.

Genetic Analysis of Human Traits In Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines

M. Rivas, M. Daly, D. Altshuler, 2008, PLoS genetics.

Genome-wide discovery of transcriptional modules from DNA sequence and gene expression

D. Koller, E. Segal, R. Yelensky, 2003, ISMB.

Comprehensive Genomic Profiling (CGP) of Angioimmunoblastic T-Cell Lymphoma (AITL) to Prospectively Inform Diagnosis and Clinical Management

R. Yelensky, D. Lipson, V. Miller, 2015 .

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

P. Stephens, R. Yelensky, L. Pusztai, 2014, The oncologist.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

M. Rubin, P. Stephens, R. Yelensky, 2013, European urology.